nL-LMNB1-001

PreclinicalSmall molecule

Nn-Lorem Foundation

nL-LMNB1-001 is one of 2 small molecule programs targeting Leukodystrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukodystrophyActive, not recruiting

LeukodystrophyPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Leukodystrophy

#DrugCompanyPhaseTrials

Antisense Oligonucleotide Treatment (ASO)

MMassachusetts General Hospital

Phase 2

1 2

nL-LMNB1-001

Nn-Lorem Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Leukodystrophy

NCT06816498

Clinical

Trials by Indication[1]

Leukodystrophy1 trial

An Open-label, Single-center, Single-participant Study of an Experimental Antisense Oligonucleotide Treatment for a Patient With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)

Active, not recruiting·Nn-Lorem Foundation·Preclinical·NCT06816498·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nL-LMNB1-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nL-LMNB1-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nL-LMNB1-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — n-Lorem Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Nn-Lorem Foundation

nL-LMNB1-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Leukodystrophy1 trial

References

Drug Info

Quick Facts

Related News